603567 Stock Overview
Heilongjiang ZBD Pharmaceutical Co., Ltd. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 5/6 |
Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Heilongjiang ZBD Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥12.09 |
52 Week High | CN¥13.63 |
52 Week Low | CN¥8.89 |
Beta | 0.29 |
1 Month Change | -0.25% |
3 Month Change | -2.42% |
1 Year Change | -0.58% |
3 Year Change | -20.98% |
5 Year Change | -2.74% |
Change since IPO | -54.56% |
Recent News & Updates
Recent updates
Shareholder Returns
603567 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | 0.5% | -1.9% | -0.6% |
1Y | -0.6% | -5.7% | 8.3% |
Return vs Industry: 603567 exceeded the CN Pharmaceuticals industry which returned -5.7% over the past year.
Return vs Market: 603567 underperformed the CN Market which returned 8.3% over the past year.
Price Volatility
603567 volatility | |
---|---|
603567 Average Weekly Movement | 5.9% |
Pharmaceuticals Industry Average Movement | 7.3% |
Market Average Movement | 8.7% |
10% most volatile stocks in CN Market | 12.9% |
10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 603567 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603567's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 2,545 | Jiujiang Yan | www.zbdzy.com |
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.
Heilongjiang ZBD Pharmaceutical Co., Ltd. Fundamentals Summary
603567 fundamental statistics | |
---|---|
Market cap | CN¥11.35b |
Earnings (TTM) | CN¥653.39m |
Revenue (TTM) | CN¥3.12b |
17.4x
P/E Ratio3.6x
P/S RatioIs 603567 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
603567 income statement (TTM) | |
---|---|
Revenue | CN¥3.12b |
Cost of Revenue | CN¥1.67b |
Gross Profit | CN¥1.45b |
Other Expenses | CN¥792.19m |
Earnings | CN¥653.39m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 26, 2025
Earnings per share (EPS) | 0.70 |
Gross Margin | 46.37% |
Net Profit Margin | 20.96% |
Debt/Equity Ratio | 40.5% |
How did 603567 perform over the long term?
See historical performance and comparisonDividends
1.7%
Current Dividend Yield29%
Payout RatioCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/29 13:31 |
End of Day Share Price | 2024/12/27 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Heilongjiang ZBD Pharmaceutical Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Wen Wen Shen | Avic Securities Co., Ltd |
Song Yang | Tianfeng Securities Brokerage Co., Ltd |